Arbutus Biopharm Stock Price, News & Analysis

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Dr. Tram Tran has resigned from its Board of Directors, effective February 26, 2023, to transition into public service. Dr. Tran, a board member since November 2021, was part of the Executive Compensation and Human Resources Committee, contributing her expertise in virology to the company's hepatitis B and COVID-19 pipeline. The resignation was amicable and not due to any disagreements. The company is initiating a search for a new independent board member to fill her vacancy. Arbutus focuses on developing therapeutics for Hepatitis B and coronaviruses, including its lead candidate, AB-729.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its 2023 objectives, focusing on advancing its HBV assets, AB-101 and AB-161, into Phase 1 clinical trials and expecting data from ongoing AB-729 trials. The company anticipates significant data from multiple Phase 2a trials in 2023 and plans to advance AB-343, a new coronavirus asset, into clinical trials. As of December 31, 2022, Arbutus had approximately $185 million in cash, providing a runway into Q4 2024. The company aims to address unmet needs in HBV and coronavirus treatment.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced promising preliminary data from the lead-in phase of its Phase 2a clinical trial for AB-729, targeting chronic Hepatitis B virus (cHBV). With 43 patients enrolled, the initial results show a 1.51 log decline in HBsAg after 16 weeks, similar to Phase 1b results. The treatment, combined with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a, demonstrates a safe profile. The company expects to release further results from the trial's IFN phase in the first half of 2023, underscoring its commitment to addressing chronic HBV infection.

Arbutus Biopharma Corporation (ABUS) reported strong cash reserves of $190.2 million as of September 30, 2022, sufficient to fund operations into Q2 2024. The company showcased promising data on its RNAi therapeutic AB-729, indicating long-term control of HBV biomarkers. Total revenue increased 79% year-over-year to $6.0 million, driven by collaborations. However, the net loss decreased from $24.2 million to $17.6 million, reflecting a loss per share of $0.12. Despite challenges from COVID-19, the company is on track to achieve milestones in its clinical pipeline by year-end.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 am GMT / 6:30 am EDT. The presentation will be accessible via a live webcast on Arbutus' website, with an archived replay available afterward. Arbutus is focused on developing therapeutics for viral diseases, particularly Hepatitis B and coronaviruses, with key compounds like AB-729 currently in phase 2 clinical trials.

Arbutus Biopharma (ABUS) announced promising findings from clinical trials of its RNAi therapeutic, AB-729, showing sustained HBV suppression in patients up to 44 weeks after treatment cessation. Additionally, preclinical data for AB-101, an oral PD-L1 inhibitor, indicate improved HBV immune response when combined with RNAi therapy. However, the company has halted AB-836 development due to safety concerns. Upcoming poster presentations at the AASLD – The Liver Meeting will detail these findings. A conference call is scheduled for November 4, 2022, to discuss these results.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that it will present three posters with clinical data at the AASLD Liver Meeting 2022 from November 4-8 in Washington, DC. The presentations will cover findings from its lead compound AB-729 and the preclinical PD-L1 inhibitor AB-101. Key data highlights include:

• Long-term HBV control in patients after stopping nucleos(t)ide analogue therapy.
• Increased immune responses in HBV-infected mice with combined treatment.
• Interim analysis of a Phase 2 study showing safety in various treatment combinations.

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the third quarter 2022 financial results and corporate update, set for November 9, 2022. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET.

The company focuses on developing therapeutics for viral diseases, including HBV and SARS-CoV-2. Notably, its lead compound AB-729 is undergoing evaluation in multiple phase 2 clinical trials.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Chief Development Officer Gaston Picchio will depart for personal reasons effective December 31, 2022. The company has begun the search for his successor. CEO William Collier expressed gratitude for Dr. Picchio's contributions, particularly in advancing the clinical pipeline targeting chronic hepatitis B virus (HBV). Arbutus focuses on developing therapeutics aimed at HBV and other viral diseases, including its lead RNAi therapeutic, AB-729, currently in multiple Phase 2 clinical trials.